Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Changes have been proposed to the quality payment program that could have ups and downs, but not, perhaps for some, until ...

Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes ...

University of Washington’s Peter Rabinowitz, M.D., M.P.H.. sees a world awash in emerging diseases and climate change data ...

The list includes dengue fever, chikungunya, leptospirosis and Valley fever, says University of Washington professor Peter ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy ...

Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more ...

Up to half of patients showed significant improvement in study results presented at the American Academy of Ophthalmology ...